Semaglutide is generally preferred over liraglutide for weight loss and blood sugar control in people with obesity and type 2 diabetes because studies directly comparing the two medications have shown that semaglutide leads to significantly more weight loss and better glycemic control
External resources FDA Prescribing Information for Zepbound (tirzepatide) including OSA indication SURMOUNT-OSA Trial Results (New England Journal of Medicine) For researchers serious about optimizing every aspect of their peptide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides covering side effect management, dosing optimization, and community support from thousands of experienced researchers
The personalized treatment plan accounts for prior GLP-1 history, BMI, and tolerability
Always check the expiration date before use
As part of overall weight loss, patients may notice a reduction in belly fat, though the extent of fat loss can vary based on individual factors like genetics, diet, and exercise habits
